Homology Medicines Inc (35H)

1.4885
+0.0015(+0.10%)
  • Volume:
    0
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    1.4885 - 1.5155

35H Overview

Prev. Close
1.487
Day's Range
1.4885-1.5155
Revenue
2.99M
Open
1.5155
52 wk Range
1.277-5.8
EPS
-0.021
Volume
0
Market Cap
86.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
375
P/E Ratio
-140.78
Beta
-0.368
1-Year Change
-74.58%
Shares Outstanding
57,402,028
Next Earnings Date
-
What is your sentiment on Homology Medicines?
or
Market is currently closed. Voting is open during market hours.

Homology Medicines Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Homology Medicines Inc Analysis

Homology Medicines Inc Company Profile

Homology Medicines Inc Company Profile

Employees
205
  • Type:Equity
  • Market:Germany
  • ISIN:US4380831077
  • WKN:A2JGTY

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Read More

Analyst Price Target

Average12.1375 (+722.88% Upside)
High29
Low3.1
Price1.475
No. of Analysts8
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • This stock is taking way too long to do anything. ☹️
    0
    • Bought some of Fixx, easily double or triple by end of this year.
      0
      • whats wrong with Fixx???
        0
        • apparently they diluted some new shares on a public offer, its gonna come back high soon, they just did a conference about their had 210,103,203, we shall see, I bought a lot of it
          0
      • will bull like crazy soon now
        0
        • You hope?
          0
        • 0
      • down in a few again
        0